Kornimate/medical-research-clean huggingface dataset:
use of alexa as a cognitive aid for emergency front of neck access (fona)

Conditions: Intubation; Difficult or Failed

Summary: the aim of the study is to investigate whether a voice activated cognitive aid can improve performance in a simulated emergency front-of-neck access scenario. this skill is ideally practiced on an annual basis by anaesthetists in training, with a variety of usually low-fidelity simulation used. the addition of the alexa cognitive aid is a novel step with the aim of improving adherence to the recommended steps required to successfully complete the procedure. one arm of this study will be introduced to the alexa checklist in advance of performing the procedure prior to crossover, whereas the second arm will not (subject to standard anaesthetic training).


Eligibility criteria:
inclusion criteria: * ct1 to consultant level anaesthetists, who have completed the initial assessment of competencies (iac) exclusion criteria: * anaesthetists without the above criteria, refusal
benzamide derivates as treatment of clozapine-induced hypersalivation

Conditions: Clozapine-induced Hypersalivation

Summary: hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable adverse effect of clozapine therapy, and until now there is not enough effective treatment for this side effect leading to noncompliance. in previous studies it was found that substitute benzamide derivatives with higher selective binding to the d2/d3 dopamine receptor - amisulpride and sulpiride may be effective in treatment of clozapine-induced hypersalivation (cih). today, in psychiatric practice in israel, there are four medications which belong to substitute benzamide derivatives group: amisulpride, sulpiride, tiapride and moclobemide. we hypothesized that antisalivation effect is universal for the whole group of benzamide. the aim of our study was to compare efficacy of amisulpride, moclobemide (reversible monoamine oxidase inhibitor-a (rimas)), and tiapride (dopamine d2 antagonist) as an additional possibility for management of cih.

the pilot study will be conducted in two mental health centers. in order to examine our hypothesis, we will use an add-on design. into the study will be enrolled 50 patients with schizophrenia and schizoaffective disorder (males and females, 19-60 years old), according to the dsm-iv criteria, treated with clozapine and suffering from hypersalivation.

Eligibility criteria:
inclusion criteria: * age 18-60 years, male or female * dsm-iv criteria for schizophrenia * clozapine treatment * at least 2 scores on the nocturnal hypersalivation rating scale (nhrs) exclusion criteria: * evidence of organic brain damage, mental retardation, alcohol or drug abuse
a double-blind, placebo-controlled study with open-label follow-up to determine the safety and efficacy of subcutaneous doses of r-huepo in aids patients with anemia induced by their disease and azt therapy

Conditions: HIV Infections; Cytopenias

Summary: to determine the safety and efficacy of erythropoietin administered subcutaneously to aids patients with anemia secondary to their disease and/or concomitant zidovudine (azt) therapy. efficacy will be assessed by correction of anemia and decrease in transfusion requirements.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * maintenance dose of zidovudine (azt) of at least 400 mg daily. exclusion criteria co-existing condition: patients with the following are excluded: * history of any primary hematologic disease. * clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying aids. * aids-related dementia. * uncontrolled hypertension (diastolic blood pressure \> 100 mmhg). * presence of concomitant iron deficiency. * anemia attributable to factors other than aids or zidovudine (azt) therapy. * acute opportunistic infection. * history of seizures. patients with clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying aids are excluded. * must not have previously participated in any other r-huepo clinical studies. prior medication: excluded within 30 days of study entry: * experimental drug or experimental device. * cytotoxic chemotherapy. * excluded within 2 months of study entry: * androgen therapy. clinical diagnosis of aids and related anemia. * clinical diagnosis of aids. * clinically stable for 1 month preceding study entry. * maintenance dose of zidovudine (azt) of at least 400 mg daily. substance abuse.

Keywords: recombinant proteins injections, subcutaneous erythropoietin acquired immunodeficiency syndrome anemia zidovudine
the relationship between systemic immune inflammation index and disease activity in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: in this study, the aim was to investigate the relationship between sii and other laboratory parameters with disease activity in as patients and to discuss its usability in the follow-up and treatment process.

this study aimed to investigate the relationship between the systemic immune inflammation index (sii), platelet-to-lymphocyte ratio (plr), neutrophil-to-lymphocyte ratio (nlr), and disease activity and functional status in patients with ankylosing spondylitis (as). a cross-sectional clinical study was conducted, and a total of 90 patients diagnosed with as according to the modified new york criteria, aged between 18 and 65, who presented to our outpatient clinics were included in the study. demographic data, disease duration, age at symptom onset, and laboratory parameters, including platelet, neutrophil, basophil, eosinophil, lymphocyte counts, mean platelet volume (mpv), red blood cell distribution width (rdw), c-reactive protein (crp), and erythrocyte sedimentation rate (esr), were recorded. nlr and plr values were calculated. the systemic immune inflammation index (sii) was calculated by dividing the product of neutrophil and platelet counts by the lymphocyte count. we investigated all of these parameters and disease activity scores. disease activity was assessed with the bath ankylosing spondylitis disease activity index (basdai), spinal mobility with the bath ankylosing spondylitis metrology index (basmi), and functional status with the bath ankylosing spondylitis functional index (basfi). in addition, during the routine follow-ups of patients, requested blood tests were examined, and platelet, neutrophil, basophil, eosinophil, lymphocyte counts, mean platelet volume (mpv), rdw (red blood distribution width), crp, and esr values will be recorded. neutrophil-lymphocyte ratio (nlr), platelet-lymphocyte ratio (plr), and systemic immune inflammation index (sii) were calculated

Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 65 who have been diagnosed with ankylosing spondylitis according to the modified new york criteria, have applied to the istanbul physical medicine and rehabilitation training and research hospital outpatient clinic on the specified dates, meet the exclusion criteria, and have complete blood count, crp, and esr values in their hospital records. exclusion criteria: * presence of acute or chronic infection * presence of autoimmune diseases other than ankylosing spondylitis * pregnancy * diabetes * chronic kidney disease * chronic liver disease * malignancy * cardiovascular disease * hematological disease

Keywords: ankylosing spondylitis complete blood count inflammation
human leukocyte antigen (hla)-haploidentical hematopoietic stem cell transplantation for patients with aplastic anemia

Conditions: Aplastic Anemia

Summary: rationale: chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of hla-haploidentical allogeneic hematopoietic cell transplantation. in addition, depletion cd3±cd19 cells may contribute to prevent developing severe acute graft versus host disease (gvhd) in haploidentical transplantation. purpose: this phase i/ii trial is to evaluate the safety and efficacy of fludarabine, cyclophosphamide and antithymocyte globulin with cd3±cd19 depleted graft from haploidentical donors in treating patients with aplastic anemia.


Eligibility criteria:
inclusion criteria: * diagnosis of life-threatening marrow failure (severe aplastic anemia) of nonmalignant etiology meeting 2 of the following criteria: * granulocyte count \< 500/mm3, * corrected reticulocyte count \< 1%, * platelet count \< 20,000/mm3 * no hla-identical family member or closely matched (8 of 8 hla-locus match) unrelated marrow donor available * hla-haploidentical related donor available exclusion criteria: * paroxysmal nocturnal hemoglobinuria or fanconi anemia * clonal cytogenetic abnormalities or myelodysplastic syndromes * active fungal infections * hiv positive * severe disease other than aplastic anemia that would severely limit the probability of survival during the graft procedure * pregnant or nursing

Keywords: aplastic anemia fludarabine cd3±cd19 depletion haploidentical hematopoietic stem cell transplantation
management of postoperative pain after total hip arthroplasty

Conditions: Osteoarthritis of Hip

Summary: orthopedic surgery is reportedly among the most painful surgical procedures. surgical damage following major orthopedic surgery often involves a large, deep incision with considerable tissue dissection and muscle, bone, and vascular exposure. post-operative pain after such surgery is exacerbated on movement or by reflex spasms of the muscles, which may delay mobilization, reduce satisfaction, prolong hospitalization, and possibly increase medical costs. we design a prospective randomized study for postoperative pain control following total hip arthroplasty.


Eligibility criteria:
inclusion criteria: * diagnosed for surgery of osteoarthritis of hip * ability to tolerate surgery under general anesthesia. exclusion criteria: * refusal or the lack of mental ability to provide informed consent * neuropathic pain or sensory disorders in the leg requiring surgery * previous surgery of the hip joint * coagulation abnormalities * severe renal or hepatic impairment * chronic opioid users * known history of intolerance to the drugs used in the study
psychoeducation of parents to children with fasd

Conditions: Fetal Alcohol Spectrum Disorders; Behavior Problem; Adaptive Behavior; Learning Disorders

Summary: by longitudinal, prospective research in children and adolescents with fetal alcohol spectrum disorders (fasd) and their parents to explore the beneficial effects of participating in a standardized intervention program in order to treat and reduce the consequences of early brain damage. by using elements from international programs based on psychoeducation and parent training, the investigators aim to help parents to better understand and respond to the neurodevelopmental disabilities of their children, and thereby improving behavioral problems and self-regulation deficits.

the main aim of this research project is to evaluate the effects of a standardized intervention program for parents and professionals working with children and adolescents with fasd. focus will be on care-persons' knowledge and skills and psychoeducation with regard to improved handling of behavioral problems and deficits in self-regulation due to fasd. to achieve this aim objectives will be: * to collect and analyse data on family empowerment, parenting skills and stress before and after participation in the intervention program. * to collect and analyse data on the child's behavior and deficits in self-regulation before and after participation in the intervention program. * to collect and analyse data on professionals' knowledge of fasd before and after participation in the intervention program. the current study hypothesizes that caregivers who understand and view their children's behavior from a neurodevelopmental perspective are more likely to feel competence, use antecedent strategies, and thereby reduce child problem behavior and improve functional outcome (fig. 2). the investigators hypothesize that participation in this program will improve parental empowerment and child self-regulation and behavior compared with baseline assessments.

Eligibility criteria:
all children and adolescents (age 2,5-18 years) referred to the regional competence centre for children with prenatal alcohol exposure in arendal, norway will be invited to participate in the current research project. inclusion criteria: * valid information about alcohol exposure in fetal life. exceptions to this inclusion criterion are children who have been adopted and with dysmorphic features that are consistent with full fetal alcohol syndrome. exclusion criteria: * children with known genetic syndromes, progressive brain and neuromuscular diseases or major sensory defects (blindness or deafness).

Keywords: fasd psychoeducation parenting information program
survey to describe impact of reflux disease on everyday life in gerd patients before and after 4 weeks treatment.

Conditions: Gastroesophageal Reflux Disease

Summary: to describe the change of impact of reflux symptoms on the everyday life perceived by patients before and after 4 weeks treatment by using gerd impact scale questionnaire (gis) by total gerd patient population and by treatment group; and to describe the concordance between patient-reported and physician-reported symptom load.


Eligibility criteria:
inclusion criteria: * patients with gerd diagnosed clinically or by endoscopy and prescribed with medical treatments * provision of written informed consent exclusion criteria: * patients cannot read and/or understand gis * patients with the history or symptoms of peptic ulcer, gastrointestinal cancer, serious or malignant diseases (anorexia, weight loss, anemia, fever ...)

Keywords: gerd reflux symptom heartburn acid regurgitation ppi h2ra antacid
dehydroepiandrosterone (dhea) + acolbifene against vasomotor symptoms (hot flushes) in postmenopausal women

Conditions: Vasomotor Symptoms; Hot Flushes

Summary: the purpose of this phase iii trial is to evaluate the efficacy of oral administration of dehydroepiandrosterone (dhea) combined with acolbifene (a selective estrogen receptor modulator (serm)) on vasomotor symptoms (hot flushes) in postmenopausal women.


Eligibility criteria:
main inclusion criteria: * postmenopausal women (non-hysterectomized or hysterectomized). * women between 40 and 75 years of age. * willing to participate in the study and sign an informed consent. * women having many moderate to severe hot flushes. * for non-hysterectomized women, willing to have an endometrial biopsy at baseline and end of-study. main exclusion criteria: * undiagnosed abnormal genital bleeding. * hypertension equal to or above 140/90 mm hg. * the administration of any investigational drug within 30 days of screening visit. * endometrial hyperplasia (simple or complex hyperplasia with or without atypia), cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening.

Keywords: hot flush(es) hot flash(es) vasomotor symptoms dehydroepiandrosterone (dhea) prasterone acolbifene selective estrogen receptor modulator (serm) antiestrogen menopause postmenopausal women
group training and quality of life and reduction of pain in rheumatoid arthritis patients

Conditions: Training Leaflet; Training Workshop

Summary: abstract background: it is documented that some patient education interventions, preferably with a behavioral component included, may improve pain, disability and moods purpose of the study: the purpose of this study was to improve the quality of life and reduce pain in rheumatoid arthritis patients. methods: patients were allocated to a patient training intervention group and patient without training intervention group. both groups received routine treatments while the patient training intervention group, in addition to the routine treatments received training booklets and participated in the training workshop. all the extracted data from the written questionnaire were collected and analyzed using spss software.

results: the improvement in the signs of recovery for physical and mood symptoms in the patient training intervention group were seen (p \< 0.05). the score of quality of life had significantly improved in the two groups (mean difference was 9.31±3.03 and p\<0.003). this improvement was significantly higher in the patient training intervention group (p=0.008). after adjustment for education level, the score of quality of life in patient training intervention group had a higher improvement, but the difference between the two groups was not significant (p = 0.1). conclusions: this study showed the important role of training and the patients' educational level on better treatments. the appropriate training in the patient could create a change in the treatment process and has a better effect on quality of life.

Eligibility criteria:
inclusion criteria: * the only inclusion criterion was that the patient had ra as the main disease (with the same duration and severity of disease). exclusion criteria: * patients were excluded if they had another disease.

Keywords: patient training rheumatoid arthritis quality of life
treatment of cervical intraepithelial neoplasia (cin) grade iii with non-invasive physical plasma

Conditions: Cervical Intraepithelial Neoplasia III

Summary: the aim of the prospective, unicenter proof-of-principle study is to investigate the anti-neoplastic effectiveness of nipp against cin iii lesions. * the aim of this project is to evaluate the potential of a previous nipp treatment to significantly reduce the invasiveness of the leep excision. * another aim of this study is to investigate cellular / molecular effects of nipp following the in-vivo treatment of the cervix using molecular biological methods. for this purpose, tissue treated with plasma is taken after defined periods of time by mini biopsy and examined using molecular biological, histological and microscopic methods.

cervical intraepithelial neoplasms (cin), classified into severity levels cin i to iii, can be precursors to cervical cancer (cc), the world's third most common cancer in women (270,000 deaths / year), which radical therapies are often associated with lifelong severe physical and emotional stress. cross-sectional studies found a prevalence for cin of 62 per 1,000 women and incidences of 1.2 (cin i), 0.8 (cin ii) and 0.7 (cin iii) per 1,000 women per year (highest incidence of cin between 20 and 24 years) age). the standard therapy for the treatment of cin iii by leep excision is associated with an increase in mortality of 17%. cin iii, in particular, is associated with a significant decline in quality of life, psychological well-being and sexual health, although on average only about 12% of cin iii lesions progress to invasive cc. the resulting over-treatment (in around 8-9 out of 10 patients) with invasive procedures is a serious problem for affected women, health care providers and the health economy. the nipp treatment is a tissue-sparing, pain-free, easy to carry out and outpatient treatment method without anesthesia and hospitalization. a non-randomized, one-arm feasibility study at the department of women's health (649 / 2017bo1) already showed the effectiveness of a nipp treatment. clinical implications for cin iii: * a previous nipp treatment should significantly reduce the invasiveness of the leep excision. * if the oncological safety of nipp treatment is comparable (histological complete remission of cin iii), nipp is to be established as a safe alternative to leep excision in the future.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histologically confirmed cin iii * clearly visible transformation zone of the portio and margins of the lesions according to t1 / t2 * signed written consent exclusion criteria: * not fully visible transformation zone * indication of an invasive disease * serious cardiovascular diseases * patients who only want to undergo a leep excision
a trial of aprepitant for prevention of post-endoscopic retrograde cholangiopancreatography (ercp) pancreatitis

Conditions: Pancreatitis

Summary: the purpose of this study is to determine if giving aprepitant 4 hours before and for two days after ercp decreases the risk of developing pancreatitis after ercp.

this study involves taking a drug aprepitant by mouth 4 hours before the ercp and once a day for two days after the ercp, in an attempt to reduce the risk of pancreatitis caused by ercp. pancreatitis, or injury and inflammation of the pancreas, is the most common complication of ercp and occurs in approximately 6 out of every 100 patients undergoing ercp. it may result in pain and lead to hospitalization and, in some cases, a need for further procedures such as surgery. aprepitant is a medication that is currently used to prevent nausea and vomiting in some patients caused by chemotherapy for the treatment of cancer. it is also approved for the prevention of post-operative nausea and vomiting. there is theoretical evidence from animal studies that the way in which aprepitant works in the body may prevent pancreatitis.

Eligibility criteria:
inclusion criteria: patients selected for the study will be those undergoing ercp who are at high risk for development of post-ercp pancreatitis * patients expected to undergo a sphincterotomy * patients with suspected sphincter of oddi dysfunction * patients with a known history in the past of post-ercp pancreatitis * patients less than 60 years of age exclusion criteria: * active pancreatitis * if they are pregnant * known adverse reaction to aprepitant

Keywords: pancreatitis